Nonhuman primate models of Parkinson's disease.
暂无分享,去创建一个
[1] J. Schneider,et al. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[2] G. Gerhardt,et al. Dopaminergic therapy improves upper limb motor performance in aged rhesus monkeys , 2000, Annals of neurology.
[3] J. Langston,et al. Model fusion: The next phase in developing animal models for parkinson’s disease , 2007, Neurotoxicity Research.
[4] H. Bergman,et al. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.
[5] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[6] E. Richfield,et al. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. , 2002, Neurotoxicology.
[7] A. Kupsch,et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline , 2001, Journal of Neural Transmission.
[8] D. Eidelberg,et al. Basal ganglia lesions after MPTP administration in rhesus monkeys , 2006, Neurobiology of Disease.
[9] A. Brownell,et al. Functional imaging of the dopamine system: in vivo evaluation of dopamine deficiency and restoration. , 2002, Neurotoxicology.
[10] M. Laruelle,et al. Dopaminergic Receptor Function Defined by Studying Genetically Altered Mice , 2003 .
[11] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[12] J. Schneider,et al. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys , 1990, Brain Research.
[13] B. Rosen,et al. Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging , 2005, Psychopharmacology.
[14] Timothy Sendera,et al. Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.
[15] Erwan Bezard,et al. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies , 2001, Nature Reviews Neuroscience.
[16] E. Bézard,et al. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey , 2000, Journal of Neuroscience Methods.
[17] K. Lyons,et al. Early detection of probable idiopathic Parkinson's disease: II. A prospective application of a diagnostic test battery , 2000, Movement disorders : official journal of the Movement Disorder Society.
[18] D. E. Redmond,et al. Spontaneous Blink Rates Correlate with Dopamine Levels in the Caudate Nucleus of MPTP-Treated Monkeys , 1999, Experimental Neurology.
[19] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[20] J. Kordower,et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys , 2006, Annals of neurology.
[21] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[22] W. Rayens,et al. Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys , 2007, Neurobiology of Aging.
[23] P. James. An Essay on the Shaking Palsy , 1817, The Medico-Chirurgical Journal and Review.
[24] J. Mazziotta,et al. Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion , 1995, Brain Research.
[25] Yi Ai,et al. Correlation of R2 with total iron concentration in the brains of rhesus monkeys , 2005, Journal of magnetic resonance imaging : JMRI.
[26] J R Moeller,et al. Early differential diagnosis of Parkinson's disease with 18F‐fluorodeoxyglucose and positron emission tomography , 1995, Neurology.
[27] André Parent,et al. Comparative neurobiology of the basal ganglia , 1986 .
[28] M. Emborg,et al. CHAPTER 9 – Nonhuman Primate Models for Testing Gene Therapy for Neurodegenerative Disorders , 2006 .
[29] G. Gerhardt,et al. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys , 2002, Neurobiology of Aging.
[30] D. Price,et al. Age-related changes in multiple neurotransmitter systems in the monkey brain , 1989, Neurobiology of Aging.
[31] K. Jellinger,et al. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. , 1991, Molecular and chemical neuropathology.
[32] S. Markey. MPTP, a neurotoxin producing a Parkinsonian syndrome , 1986 .
[33] Jeffrey H Kordower,et al. Proteasome inhibition and Parkinson's disease modeling , 2006, Annals of neurology.
[34] G. di Chiro,et al. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys , 1994, Annals of neurology.
[35] S. Snyder,et al. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.
[36] P. Carvey,et al. Progressive Dopamine Neuron Loss in Parkinson's Disease: The Multiple Hit Hypothesis , 2006, Cell transplantation.
[37] Scott Deitchman,et al. Recommendations for prevention of and therapy for exposure to B virus (cercopithecine herpesvirus 1). , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] J. Eberling,et al. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. , 2003, Frontiers in bioscience : a journal and virtual library.
[39] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[40] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[41] M. C. Newman,et al. Early detection of probable idiopathic Parkinson's disease: I. development of a diagnostic test battery , 2000, Movement disorders : official journal of the Movement Disorder Society.
[42] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[43] T. Nagatsu,et al. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.
[44] J. Langston,et al. Investigating levodopa-induced dyskinesias in the parkinsonian primate. , 2000, Annals of neurology.
[45] J. Growdon,et al. Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.
[46] H. Ehringer,et al. Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems , 2005, Klinische Wochenschrift.
[47] J. Miklossy,et al. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys , 2006, Experimental Neurology.
[48] J W Langston,et al. Parkinson disease in twins: an etiologic study. , 1999, JAMA.
[49] Walle J. H. Nauta,et al. Contemporary Research Methods in Neuroanatomy , 1970, Springer Berlin Heidelberg.
[50] P. Suzdak,et al. Systemic Administration of the Immunophilin Ligand GPI 1046 in MPTP-Treated Monkeys , 2001, Experimental Neurology.
[51] D B Calne,et al. Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices , 1993, Annals of neurology.
[52] J. Kordower,et al. Age‐related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: Relevance to selective neuronal vulnerability , 2007, The Journal of comparative neurology.
[53] Hagai Bergman,et al. Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates , 1999, Experimental Brain Research.
[54] P. Hof,et al. Aging in nonhuman primates , 2002 .
[55] P. Pivirotto,et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[56] A. Singleton,et al. Genetics of Parkinson's disease and parkinsonism , 2006, Annals of neurology.
[57] Sanford P. Markey,et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.
[58] V. Dhawan,et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[59] A. Peters,et al. The effect of aging on pars compacta of the substantia nigra in rhesus monkey. , 1999, Journal of neuropathology and experimental neurology.
[60] C. Rebert,et al. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.
[61] Jeffrey H Kordower,et al. Neural Repair Strategies for Parkinson's Disease: Insights from Primate Models , 2006, Cell transplantation.
[62] H. Braak,et al. Parkinson's disease: premotor clinico-pathological correlations. , 2006, Journal of neural transmission. Supplementum.
[63] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[64] B. Jenkins,et al. Mapping Dopamine Function in Primates Using Pharmacologic Magnetic Resonance Imaging , 2004, The Journal of Neuroscience.
[65] N. Satoh,et al. Acute effects of a parkinsonism-inducing neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mouse body temperature. , 1987, Life sciences.
[66] R. Roth,et al. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment , 1999, Neuroscience.
[67] Bruce G. Jenkins,et al. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease , 1998, Nature Medicine.
[68] R. Ridley,et al. Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson’s disease in marmoset monkeys , 2003, Experimental Neurology.
[69] C. Sachs,et al. ACTIONS OF 6‐HYDROXYDOPAMINE QUINONES ON CATECHOLAMINE NEURONS 1 , 1975, Journal of neurochemistry.
[70] A. Antonini,et al. Preoperative indicators of clinical outcome following stereotaxic pallidotomy , 1997, Neurology.
[71] A. Björklund,et al. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[72] M. Zigmond,et al. Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. , 1989, International review of neurobiology.
[73] M. Allam,et al. Parkinson's disease risk factors: genetic, environmental, or both? , 2005, Neurological research.
[74] S. Udenfriend,et al. TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. , 1964, The Journal of biological chemistry.
[75] J. Langston,et al. Aging and the nigrostriatal dopamine system: a non-human primate study. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[76] K. Gwinn‐Hardy,et al. The role of radiotracer imaging in Parkinson disease , 2005, Neurology.
[77] S. Shelton,et al. Noninvasive assessment of aromatic L‐amino acid decarboxylase activity in aging rhesus monkey brain in vivo , 2001, Synapse.
[78] Andre Parent,et al. Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.
[79] R. Bakay,et al. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: Diminished compensatory mechanisms as a prelude to parkinsonism , 2007, Neurobiology of Disease.
[80] J. Obeso,et al. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration , 1994, Neuroscience Letters.
[81] P. Jenner. The MPTP-treated primate as a model of motor complications in PD , 2003, Neurology.
[82] I. Pigarev,et al. Nocturnal sleep structure and temperature slope in MPTP treated monkeys , 1999, Journal of Neural Transmission.
[83] M. Hallett,et al. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I , 2007, Journal of neuropathology and experimental neurology.
[84] G. Petzinger,et al. The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.
[85] J. Kordower,et al. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism , 2005, Experimental Neurology.
[86] U. Ungerstedt,et al. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.
[87] Don M. Gash,et al. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys , 1995, Neurobiology of Aging.
[88] E. Domino,et al. MPTP-Induced Hemiparkinsonism in Nonhuman Primates 6–8 Years after a Single Unilateral Intracarotid Dose , 1998, Experimental Neurology.
[89] A. Lang,et al. The proteasomal inhibition model of Parkinson's disease: “Boon or bust”? , 2006, Annals of neurology.
[90] P. Reier,et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[91] Greg A. Gerhardt,et al. Age-related changes in potassium-evoked overflow of dopamine in the striatum of the rhesus monkey , 1995, Neurobiology of Aging.
[92] P. Barry,et al. B-Virus (Cercopithecine herpesvirus 1) Infection in Humans and Macaques: Potential for Zoonotic Disease , 2003, Emerging infectious diseases.
[93] S. Straus,et al. Publication of guidelines for the prevention and treatment of B virus infections in exposed persons. , 1995, MMWR. Morbidity and mortality weekly report.
[94] J. Langston,et al. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. , 1993, Advances in neurology.
[95] Long-term MPTP-treated monkeys are resistant to GM1 systemic therapy. , 1994, Molecular and chemical neuropathology.
[96] M. LeDoux. Animal models of movement disorders , 2005 .
[97] M. Emborg. Evaluation of animal models of Parkinson's disease for neuroprotective strategies , 2004, Journal of Neuroscience Methods.
[98] Thomas Wichmann,et al. Effects of Transient Focal Inactivation of the Basal Ganglia in Parkinsonian Primates , 2002, The Journal of Neuroscience.
[99] Rest tremor in rhesus monkeys with MPTP-induced parkinsonism. , 2003, Frontiers in bioscience : a journal and virtual library.
[100] William Jagust,et al. Convection-Enhanced Delivery of AAV Vector in Parkinsonian Monkeys; In Vivo Detection of Gene Expression and Restoration of Dopaminergic Function Using Pro-drug Approach , 2000, Experimental Neurology.
[101] Z. Zhang,et al. Developing a stable bilateral model of parkinsonism in rhesus monkeys , 1993, Neuroscience.
[102] D. Dickson,et al. In situ hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys—and in Lewy body-containing human brain specimens , 2003, Experimental Neurology.
[103] Richard Grondin,et al. Functional MRI studies in awake rhesus monkeys: methodological and analytical strategies , 2002, Journal of Neuroscience Methods.
[104] D. Hilt,et al. Glial Cell Line-Derived Neurotrophic Factor: A Novel Therapeutic Approach to Treat Motor Dysfunction in Parkinson's Disease , 1997, Experimental Neurology.
[105] D. Grosset,et al. The role of radiotracer imaging in Parkinson disease , 2005, Neurology.
[106] C. Olanow,et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats , 2002, Neuroreport.
[107] P. Goldman-Rakic,et al. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys , 1981, Neuroscience.
[108] David Eidelberg,et al. Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[109] S. Lipina,et al. Premorbid exercising in specific cognitive tasks prevents impairment of performance in parkinsonian monkeys , 2007, Brain Research.
[110] B. Konigsmark,et al. Methods for counting neurons , 1970 .
[111] J. Langston,et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition , 2006, Annals of neurology.
[112] K. Kashfi,et al. Cancer Prevention: A New Era beyond Cyclooxygenase-2 , 2005, Journal of Pharmacology and Experimental Therapeutics.
[113] H. Braak,et al. Pathoanatomy of Parkinson’s disease , 2000, Journal of Neurology.
[114] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[115] J. A. Roberts. The Aged Rhesus Macaque in Neuroscience Research: Importance of the Nonhuman Primate Model , 2002 .
[116] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[117] M. Nomoto,et al. Pharmacokinetics of l-dopa in plasma and extracellular fluid of striatum in common marmosets , 2003, Brain Research.
[118] Philippe Hantraye,et al. MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.
[119] T. Niwa,et al. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.
[120] R. Ridley,et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. , 2007, Brain : a journal of neurology.
[121] G. Gerhardt,et al. Motor slowing and parkinsonian signs in aging rhesus monkeys mirror human aging. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.
[122] M. Hallett,et al. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II , 2007, Journal of neuropathology and experimental neurology.
[123] M. Mishkin,et al. Aged monkeys exhibit behavioral deficits indicative of widespread cerebral dysfunction , 1991, Neurobiology of Aging.
[124] Doris J. Doudet,et al. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: A multi-tracer PET study , 2006, NeuroImage.
[125] J. Holden,et al. Age‐related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys , 1998, The Journal of comparative neurology.
[126] H. Thoenen,et al. Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine , 2004, Naunyn-Schmiedebergs Archiv für Pharmakologie und experimentelle Pathologie.
[127] S. Lipina,et al. Dissociated functional recovery in parkinsonian monkeys following transplantation of astroglial cells , 2001, Brain Research.
[128] C. Tanner,et al. Epidemiology of Parkinson’s Disease: An Overview , 2004 .
[129] D. Jacobowitz,et al. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.
[130] R. Ridley,et al. Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease , 2005, The Journal of Neuroscience.
[131] P. Goldman-Rakic,et al. Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[132] Ali H. Rajput,et al. The Neuropathology of Parkinson’s Disease and Other Parkinsonian Disorders , 2004 .
[133] S. Straus,et al. Guidelines for the prevention and treatment of B-virus infections in exposed persons. The B virus Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[134] C. Marsden,et al. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin , 1989, Neuropharmacology.
[135] Jeffrey H. Kordower,et al. The role of α-synuclein in Parkinson's disease: insights from animal models , 2003, Nature Reviews Neuroscience.
[136] Jeffrey H Kordower,et al. The role of alpha-synuclein in Parkinson's disease: insights from animal models. , 2003, Nature reviews. Neuroscience.
[137] R A Crowther,et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[138] J. Ridet,et al. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[139] O. Hornykiewicz,et al. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.
[140] D. Goldstein,et al. Sympathetic Innervation in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Primate Model of Parkinson's Disease , 2003, Journal of Pharmacology and Experimental Therapeutics.
[141] T. Südhof,et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[142] P. Jenner,et al. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. , 2003, Parkinsonism & related disorders.
[143] E. Bézard,et al. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey , 1997, Brain Research.
[144] Yi Ai,et al. Point source concentration of GDNF may explain failure of phase II clinical trial , 2006, Experimental Neurology.
[145] A. Lang,et al. Crossroads in GDNF therapy for Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[146] P. Aebischer,et al. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[147] M. Herrero,et al. Circadian Determinations of Cortisol, Prolactin and Melatonin in Chronic Methyl-Phenyl-Tetrahydropyridine-Treated Monkeys , 2003, Neuroendocrinology.
[148] V L Villemagne,et al. Loss of D2 Receptor Binding with Age in Rhesus Monkeys: Importance of Correction for Differences in Striatal Size , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[149] Anita J. Jurkowski,et al. Classification and Clinical Features of Movement Disorders , 2005 .
[150] J. Pearce. Howard Henry Tooth (1856–1925) , 2000, Journal of Neurology.
[151] W. Jagust,et al. A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes , 1998, Brain Research.
[152] J. Langston,et al. The etiology of Parkinson's disease with emphasis on the MPTP story , 1996, Neurology.
[153] A. Rajput,et al. Parkinson’s disease management strategies , 2006, Expert review of neurotherapeutics.
[154] J. Schneider. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys , 1990, Brain Research.
[155] G. Baltuch,et al. Long-Term Outcomes of Bilateral Subthalamic Nucleus Stimulation in Patients with Advanced Parkinson’s Disease , 2006, Stereotactic and Functional Neurosurgery.
[156] S. Geuna. Appreciating the difference between design‐based and model‐based sampling strategies in quantitative morphology of the nervous system , 2000, The Journal of comparative neurology.
[157] J. Bloch,et al. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons , 2004, Neurobiology of Disease.
[158] E. Hirsch,et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure , 2004, Glia.
[159] É. Hajós‐Korcsok,et al. The Effects of a Selective Dopamine D2 Receptor Agonist on Behavioral and Pathological Outcome in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Squirrel Monkeys , 2005, Journal of Pharmacology and Experimental Therapeutics.
[160] Redmond De. Cellular replacement therapy for Parkinson's disease--where we are today? , 2002 .